NCT00526045已完成1 期
A Phase I Dose Escalation, Multi-center, Open-label Study of AUY922 Administered IV on a Once Weekly Schedule in Adult Patients With Advanced Solid Malignancies Including Phase II Expansion Arms in Patients With Either HER2 Positive or ER Positive Locally Advanced or Metastatic Breast Cancer.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 117
- 试验地点
- 8
- 主要终点
- The safe dose of AUY922 when administered once a week
研究概览
简要总结
This is a phase I/II, open-label, multicenter study of AUY922 administered intravenously in patients with advanced solid malignancies to determine the maximum tolerated dose. Phase II expansion arms will investigate efficacy in patients with either HER2 positive or ER positive locally advanced or metastatic breast cancer. Additional patients with advanced solid malignancies will also be investigated in a separate expansion arm. Safety, pharmacokinetics and pharmacodynamics will be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Dose-escalation and MTD dose expansion arm: Patients with histologically confirmed, advanced malignant solid tumors whose disease has progressed on standard therapy or for whom no standard therapy exists.
- •Breast cancer phase II expansion arms only:
- •Females patients with HER2 positive non-operable locally advanced or metastatic breast cancer must have:
- •History of trastuzumab resistance, defined as either local or systemic disease progression on treatment with at least 8 weeks of a trastuzumab containing regimen.
- •Received up to 3 prior anti HER2 based regimens (i.e. trastuzumab and/or lapatinib in combination with other agents) for metastatic disease
- •Patients who develop metastases while receiving adjuvant or neo-adjuvant trastuzumab are eligible.
- •HER2 positive patients, tumor/s must demonstrate HER2 over-expression based on either:
- •Immunohistochemistry (IHC) at the 3+ level, or
- •IHC 2+ confirmed by fluorescence in-situ hybridization (FISH). Tumors tested by FISH must be positive by the specific FISH assay for the amplification of HER
- •Female patients with ER positive non-operable locally advanced or metastatic breast cancer patients who received standard sequence lines of endocrine therapy and whose disease has progressed on at least one and up to 3 lines of endocrine and/or cytotoxic therapy for advanced disease.
- •All patients must have at least one measurable lesion as defined by RECIST. Irradiated lesions are only evaluable for disease progression.
- •All patients must have progressive disease before entering the study
- •Age ≥ 18 years.
- •World Health Organization (WHO) Performance Status of ≤
- •Life expectancy of ≥ 12 weeks.
- •Absolute Neutrophil Count (ANC) 1.5 x 109/L; hemoglobin (Hgb) 9 g/dl; platelets (plt) 100 x 109/L; potassium, calcium, magnesium and phosphorus within normal limits or correctable with supplements; AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 x ULN if liver metastases are present; serum bilirubin 1.5 x ULN; serum albumin > 2.5g/dl and serum creatinine 1.5 x ULN or 24-hour clearance 50 ml/min
- •Exclusion criteria:
- •Patients with CNS metastasis which are:
- •Symptomatic or
- •Require treatment for symptom control and/or
- •Note: patients without clinical signs or symptoms of CNS involvement are not required to have a CT/MRI of the brain
- •Prior treatment with any HSP90 or HDAC inhibitor compound.
- •Patient who received systemic anti-cancer treatment prior to the first dose of AUY922 within the following time frames:
- •Chemotherapy within 4 weeks
- •Radiotherapy within 4 weeks
- •Palliative radiotherapy: within 2 weeks
- •Trastuzumab treatment within 4 weeks
- •Nitrosoureas, mitomycin and monoclonal antibodies (except trastuzumab): within 6 weeks
- •Any continuous-dosing (i.e. daily dosing, every-other-day dosing, Monday- Wednesday-Friday dosing, weekly etc) of systemic anticancer treatment for which the recovery period is not known, or investigational drugs (i.e. targeted agents) within a duration of ≤ 5 half lives of the agent and their active metabolites (if any)
- •Patients who have not recovered from side effects of previous systemic anticancer therapy to less than grade 2 CTCAE prior to the first dose.
- •Pregnant or lactating women.
- •Cardia exclusion criteria:
- •History (or family history) of long QT syndrome.
- •Mean QTc ≥ 450 msec on screening ECG
- •History of clinically manifest ischemic heart disease including myocardial infarction, stable or unstable angina, coronary arteriography or cardiac stress testing/imaging with findings consistent with coronary occlusion or infarction, ≤ 6 months prior to study start.
- •History of heart failure or left ventricular (LV) dysfunction (LVEF ≤ 45%) by MUGA or ECHO
- •Known diagnosis of HIV infection (HIV testing is not mandatory).
- •Acute or chronic liver disease, acute or chronic renal disease or other concurrent severe and/or uncontrolled medical conditions (e.g. uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol.
- •Cardiac exclusion criteria:
- •Mean QTc ≥ 450 msec on screening ECG and clinically significant ECG abnormalities including one or more of the following: left bundle branch block (LBBB), right bundle branch block (RBBB) with left anterior hemiblock (LAHB). ST segment elevations or depressions > 1mm, or 2nd (Mobitz II) or 3rd degree AV block; clinically significant ECG abnormalities including one or more of the following: left bundle branch block (LBBB), right bundle branch block (RBBB) with left anterior hemiblock (LAHB). ST segment elevations or depressions > 1mm, or 2nd (Mobitz II) or 3rd degree AV block.
- •History (or family history) of long QT syndrome, heart failure or left ventricular (LV) dysfunction (LVEF ≤ 45%) by MUGA or ECHO, history of clinically manifest ischemic heart disease including myocardial infarction, stable or unstable angina, coronary arteriography or cardiac stress testing/imaging with findings consistent with coronary occlusion or infarction, ≤ 6 months prior to study start; history or presence of atrial fibrillation, atrial flutter or ventricular arrhythmias including ventricular tachycardia or Torsades de Pointes.
- •Other protocol-defined inclusion/exclusion criteria may apply
排除标准
- 未提供
研究组 & 干预措施
Escalation
Experimental
干预措施: AUY922 2 mg/m2 (Drug)
HER2 Positive
Experimental
干预措施: AUY922 2 mg/m2 (Drug)
ER+ breast cancer
Experimental
干预措施: AUY922 2 mg/m2 (Drug)
结局指标
主要结局
The safe dose of AUY922 when administered once a week
时间窗: 54 weeks (MTD determination)
次要结局
- Efficacy of AUY922 administered once a week(Baseline, and every 2 cycles (time to document tumor progression))
- Pharmacokinetics of AUY922 and Pharmacodynamics by PET response, blood and tumor biomarkers at baseline and post-AUY922(Baseline and every 2 cycles)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
1 期
Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759Non Small Cell Lung CancerNCT03360929LYZZ Alpha Holding Ltd15
招募中
1 期
CAN1012 Combined With PD-1 in Patients With Solid TumorsAdvanced Solid TumorNCT06410703Canwell Biotech Limited71
尚未招募
1 期
HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLCNSCLC Stage IVNCT06218940Newsoara Biopharma Co., Ltd.40
终止
1 期
Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)Advanced Solid TumorsNCT03065023Merck Sharp & Dohme LLC15
终止
2 期
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT03567616AbbVie8